Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Cancer Research & Development

Imbruvica Replaces Chemo, Darzalex Boosts Standard Of Care In Front-Line CLL, Myeloma

Executive Summary

Late-breaker presentations at ASH showed that replacing chemotherapy agents with Imbruvica in CLL, and adding Darzalex to Revlimid and dexamethasone in multiple myeloma, is more effective than current standards of care in certain front-line settings.

You may also be interested in...



Janssen's Imbruvica Leads CLL Market Expansion In Europe

Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.

Keeping Track: FDA Approves First Generic Advair, But Alkermes And Sunovion Land CRLs

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track: Bad News For Bristol And Lilly, Good News For TG Therapeutics

The latest drug development news and highlights from our US FDA Performance Tracker.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Clinical Trials Cancer Research & Development
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC124282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By